Oxford Biomedica, Microsoft Pact Aims At Better, Cheaper Lentiviral Vectors
Executive Summary
Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.
You may also be interested in...
Oxford Biomedica Transforms With New Deals, R&D Pipeline, And Manufacturing Facilities
The lentivirus gene delivery company, Oxford Biomedica, is to collaborate with Juno Therapeutics on its CAR-T and TCR-T projects, adding to the UK biotech’s transformation into a debt-free company with a growing in-house product pipeline.
Why Novo Holdings Has Invested In ‘Hidden Gem’ Oxford Biomedica
Life sciences investor Novo Holdings buys 10% stake in UK gene therapy biotech.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.